Review



rosa robotic platform  (Zimmer Biomet)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 86
      Buy from Supplier

    Structured Review

    Zimmer Biomet rosa robotic platform
    Study flowchart. ( A ) Of 107 patients with IDH-wild-type glioblastoma and available HRMAS spectra, 8 were excluded because the analyzed specimen corresponded to a tumor recurrence rather than the initial diagnosis, yielding a de novo cohort of 99 patients (166 spectra). Patients were classified as biopsy-only (n = <t>35;</t> <t>stereotactic</t> sampling using the <t>ROSA</t> robotic platform, Zimmer Biomet, Warsaw, IN, USA) or resection (n = 64; including 40 gross-total, 21 near-total, and 3 subtotal resections performed under neuronavigation guidance). For each patient, when multiple spectra were available, patient-level metabolic profiles were computed as the median concentration across spectra. ( B ) Intratumoral metabolic heterogeneity was assessed in the 44 patients with at least two HRMAS spectra from the same surgical episode, yielding 107 intra-patient pairwise comparisons.
    Rosa Robotic Platform, supplied by Zimmer Biomet, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/rosa+robotic+system/120+arm+robotic/pmc13208751-94-9-12
    Average 86 stars, based on 1 article reviews
    rosa robotic platform - by Bioz Stars, 2026-09
    86/100 stars

    Images

    1) Product Images from "High-Resolution Magic Angle Spinning Metabolomic Profiling of IDH-Wild-Type Glioblastoma Reveals a Composite Surgical Sampling Signature Shaped by Clinical and Anatomical Tumor Features"

    Article Title: High-Resolution Magic Angle Spinning Metabolomic Profiling of IDH-Wild-Type Glioblastoma Reveals a Composite Surgical Sampling Signature Shaped by Clinical and Anatomical Tumor Features

    Journal: Metabolites

    doi: 10.3390/metabo16050296

    Study flowchart. ( A ) Of 107 patients with IDH-wild-type glioblastoma and available HRMAS spectra, 8 were excluded because the analyzed specimen corresponded to a tumor recurrence rather than the initial diagnosis, yielding a de novo cohort of 99 patients (166 spectra). Patients were classified as biopsy-only (n = 35; stereotactic sampling using the ROSA robotic platform, Zimmer Biomet, Warsaw, IN, USA) or resection (n = 64; including 40 gross-total, 21 near-total, and 3 subtotal resections performed under neuronavigation guidance). For each patient, when multiple spectra were available, patient-level metabolic profiles were computed as the median concentration across spectra. ( B ) Intratumoral metabolic heterogeneity was assessed in the 44 patients with at least two HRMAS spectra from the same surgical episode, yielding 107 intra-patient pairwise comparisons.
    Figure Legend Snippet: Study flowchart. ( A ) Of 107 patients with IDH-wild-type glioblastoma and available HRMAS spectra, 8 were excluded because the analyzed specimen corresponded to a tumor recurrence rather than the initial diagnosis, yielding a de novo cohort of 99 patients (166 spectra). Patients were classified as biopsy-only (n = 35; stereotactic sampling using the ROSA robotic platform, Zimmer Biomet, Warsaw, IN, USA) or resection (n = 64; including 40 gross-total, 21 near-total, and 3 subtotal resections performed under neuronavigation guidance). For each patient, when multiple spectra were available, patient-level metabolic profiles were computed as the median concentration across spectra. ( B ) Intratumoral metabolic heterogeneity was assessed in the 44 patients with at least two HRMAS spectra from the same surgical episode, yielding 107 intra-patient pairwise comparisons.

    Techniques Used: Biomarker Discovery, Sampling, Concentration Assay

    Related Articles

    other:



    Article Title: Novel application of robot-guided stereotactic technique on biopsy diagnosis of intracranial lesions
    Article Snippet: Biopsy was performed with a ROSA robotic system (Zimmer Biomet Robotics, Montpellier, France) in 35 patients, the CAS-R-2 (Tianjin Huazhi Technology Co., Ltd., Tianjin, China) in 65 patients, and the REMEBOT domestic neurosurgical robot (Beijing Baihui Weikang Technology Co., Ltd., Beijing, China) in 307 patients.

    Article Title: The ROSA knee robotic system demonstrates superior precision in restoring joint line height and posterior condylar offset compared to conventional manual TKA: a retrospective case-control study.
    Article Snippet: A single-centre, single senior surgeon retrospective comparative analysis from December 2019 to May 2023 was carried out investigating primary unilateral TKA in patients with knee osteoarthritis, performed using either the ROSA robotic system (raTKA) or the conventional manual jigbased technique (mTKA) utilizing the same prosthesis (Nexgen Legacy, Zimmer Biomet, Warsaw, IN).

    Imaging:

    Article Title: Comparative Evaluation of Sagittal Alignment in Total Knee Arthroplasty: Robot Sensor Versus Surgeon’s Eye and Influencing Factors
    Article Snippet: .. The ROSA Robotic System (Zimmer Biomet, Montreal, QC, Canada) performs bone cuts using imaging and sensor feedback. ..

    Comparison:

    Article Title: The ROSA knee robotic system demonstrates superior precision in restoring joint line height and posterior condylar offset compared to conventional manual TKA: a retrospective case-control study.
    Article Snippet: .. There is currently a requirement to build up evidence for the individual robotic systems [14]; therefore, we undertook a study to assess joint line height and PCO change specifically for the ROSA robotic system (Zimmer Biomet, Warsaw, IN) in comparison with the manual technique in cases performed by a senior surgeon using the same implant. ..

    Article Title: The ROSA knee robotic system demonstrates superior precision in restoring joint line height and posterior condylar offset compared to conventional manual TKA: a retrospective case–control study
    Article Snippet: .. There is currently a requirement to build up evidence for the individual robotic systems [ ]; therefore, we undertook a study to assess joint line height and PCO change specifically for the ROSA robotic system (Zimmer Biomet, Warsaw, IN) in comparison with the manual technique in cases performed by a senior surgeon using the same implant. ..



    Similar Products

    rosa robotic platform  (Zimmer Biomet)
    86
    Zimmer Biomet rosa robotic platform
    Study flowchart. ( A ) Of 107 patients with IDH-wild-type glioblastoma and available HRMAS spectra, 8 were excluded because the analyzed specimen corresponded to a tumor recurrence rather than the initial diagnosis, yielding a de novo cohort of 99 patients (166 spectra). Patients were classified as biopsy-only (n = <t>35;</t> <t>stereotactic</t> sampling using the <t>ROSA</t> robotic platform, Zimmer Biomet, Warsaw, IN, USA) or resection (n = 64; including 40 gross-total, 21 near-total, and 3 subtotal resections performed under neuronavigation guidance). For each patient, when multiple spectra were available, patient-level metabolic profiles were computed as the median concentration across spectra. ( B ) Intratumoral metabolic heterogeneity was assessed in the 44 patients with at least two HRMAS spectra from the same surgical episode, yielding 107 intra-patient pairwise comparisons.
    Rosa Robotic Platform, supplied by Zimmer Biomet, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/rosa+robotic+system/120+arm+robotic/pmc13208751-94-9-12
    Average 86 stars, based on 1 article reviews
    rosa robotic platform - by Bioz Stars, 2026-09
    86/100 stars
    		  Buy from Supplier
    rosa one robot  (Zimmer Biomet)
    86
    Zimmer Biomet rosa one robot
    Study flowchart. ( A ) Of 107 patients with IDH-wild-type glioblastoma and available HRMAS spectra, 8 were excluded because the analyzed specimen corresponded to a tumor recurrence rather than the initial diagnosis, yielding a de novo cohort of 99 patients (166 spectra). Patients were classified as biopsy-only (n = <t>35;</t> <t>stereotactic</t> sampling using the <t>ROSA</t> robotic platform, Zimmer Biomet, Warsaw, IN, USA) or resection (n = 64; including 40 gross-total, 21 near-total, and 3 subtotal resections performed under neuronavigation guidance). For each patient, when multiple spectra were available, patient-level metabolic profiles were computed as the median concentration across spectra. ( B ) Intratumoral metabolic heterogeneity was assessed in the 44 patients with at least two HRMAS spectra from the same surgical episode, yielding 107 intra-patient pairwise comparisons.
    Rosa One Robot, supplied by Zimmer Biomet, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/rosa+robotic+system/robot+rosa/pmc13135268-6-30-33
    Average 86 stars, based on 1 article reviews
    rosa one robot - by Bioz Stars, 2026-09
    86/100 stars
    		  Buy from Supplier
    rosa robot  (Zimmer Biomet)
    86
    Zimmer Biomet rosa robot
    Study flowchart. ( A ) Of 107 patients with IDH-wild-type glioblastoma and available HRMAS spectra, 8 were excluded because the analyzed specimen corresponded to a tumor recurrence rather than the initial diagnosis, yielding a de novo cohort of 99 patients (166 spectra). Patients were classified as biopsy-only (n = <t>35;</t> <t>stereotactic</t> sampling using the <t>ROSA</t> robotic platform, Zimmer Biomet, Warsaw, IN, USA) or resection (n = 64; including 40 gross-total, 21 near-total, and 3 subtotal resections performed under neuronavigation guidance). For each patient, when multiple spectra were available, patient-level metabolic profiles were computed as the median concentration across spectra. ( B ) Intratumoral metabolic heterogeneity was assessed in the 44 patients with at least two HRMAS spectra from the same surgical episode, yielding 107 intra-patient pairwise comparisons.
    Rosa Robot, supplied by Zimmer Biomet, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/rosa+robotic+system/robot+rosa/us12569306-41-14-19
    Average 86 stars, based on 1 article reviews
    rosa robot - by Bioz Stars, 2026-09
    86/100 stars
    		  Buy from Supplier
    rosa robotic trajectory guidance system  (Zimmer Biomet)
    86
    Zimmer Biomet rosa robotic trajectory guidance system
    Study flowchart. ( A ) Of 107 patients with IDH-wild-type glioblastoma and available HRMAS spectra, 8 were excluded because the analyzed specimen corresponded to a tumor recurrence rather than the initial diagnosis, yielding a de novo cohort of 99 patients (166 spectra). Patients were classified as biopsy-only (n = <t>35;</t> <t>stereotactic</t> sampling using the <t>ROSA</t> robotic platform, Zimmer Biomet, Warsaw, IN, USA) or resection (n = 64; including 40 gross-total, 21 near-total, and 3 subtotal resections performed under neuronavigation guidance). For each patient, when multiple spectra were available, patient-level metabolic profiles were computed as the median concentration across spectra. ( B ) Intratumoral metabolic heterogeneity was assessed in the 44 patients with at least two HRMAS spectra from the same surgical episode, yielding 107 intra-patient pairwise comparisons.
    Rosa Robotic Trajectory Guidance System, supplied by Zimmer Biomet, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/rosa+robotic+system/assistance+robotic+stereotactic/pm41621733-72-11-16
    Average 86 stars, based on 1 article reviews
    rosa robotic trajectory guidance system - by Bioz Stars, 2026-09
    86/100 stars
    		  Buy from Supplier
    rosa knee robot system  (Zimmer Biomet)
    86
    Zimmer Biomet rosa knee robot system
    Study flowchart. ( A ) Of 107 patients with IDH-wild-type glioblastoma and available HRMAS spectra, 8 were excluded because the analyzed specimen corresponded to a tumor recurrence rather than the initial diagnosis, yielding a de novo cohort of 99 patients (166 spectra). Patients were classified as biopsy-only (n = <t>35;</t> <t>stereotactic</t> sampling using the <t>ROSA</t> robotic platform, Zimmer Biomet, Warsaw, IN, USA) or resection (n = 64; including 40 gross-total, 21 near-total, and 3 subtotal resections performed under neuronavigation guidance). For each patient, when multiple spectra were available, patient-level metabolic profiles were computed as the median concentration across spectra. ( B ) Intratumoral metabolic heterogeneity was assessed in the 44 patients with at least two HRMAS spectra from the same surgical episode, yielding 107 intra-patient pairwise comparisons.
    Rosa Knee Robot System, supplied by Zimmer Biomet, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/rosa+robotic+system/robot+rosa/pmc12804221-141-11-15
    Average 86 stars, based on 1 article reviews
    rosa knee robot system - by Bioz Stars, 2026-09
    86/100 stars
    		  Buy from Supplier
    passive robotic system rosa  (Zimmer Biomet)
    86
    Zimmer Biomet passive robotic system rosa
    Study flowchart. ( A ) Of 107 patients with IDH-wild-type glioblastoma and available HRMAS spectra, 8 were excluded because the analyzed specimen corresponded to a tumor recurrence rather than the initial diagnosis, yielding a de novo cohort of 99 patients (166 spectra). Patients were classified as biopsy-only (n = <t>35;</t> <t>stereotactic</t> sampling using the <t>ROSA</t> robotic platform, Zimmer Biomet, Warsaw, IN, USA) or resection (n = 64; including 40 gross-total, 21 near-total, and 3 subtotal resections performed under neuronavigation guidance). For each patient, when multiple spectra were available, patient-level metabolic profiles were computed as the median concentration across spectra. ( B ) Intratumoral metabolic heterogeneity was assessed in the 44 patients with at least two HRMAS spectra from the same surgical episode, yielding 107 intra-patient pairwise comparisons.
    Passive Robotic System Rosa, supplied by Zimmer Biomet, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/rosa+robotic+system/120+arm+robotic/pm41527883-39-21-25
    Average 86 stars, based on 1 article reviews
    passive robotic system rosa - by Bioz Stars, 2026-09
    86/100 stars
    		  Buy from Supplier

    Image Search Results


    Study flowchart. ( A ) Of 107 patients with IDH-wild-type glioblastoma and available HRMAS spectra, 8 were excluded because the analyzed specimen corresponded to a tumor recurrence rather than the initial diagnosis, yielding a de novo cohort of 99 patients (166 spectra). Patients were classified as biopsy-only (n = 35; stereotactic sampling using the ROSA robotic platform, Zimmer Biomet, Warsaw, IN, USA) or resection (n = 64; including 40 gross-total, 21 near-total, and 3 subtotal resections performed under neuronavigation guidance). For each patient, when multiple spectra were available, patient-level metabolic profiles were computed as the median concentration across spectra. ( B ) Intratumoral metabolic heterogeneity was assessed in the 44 patients with at least two HRMAS spectra from the same surgical episode, yielding 107 intra-patient pairwise comparisons.

    Journal: Metabolites

    Article Title: High-Resolution Magic Angle Spinning Metabolomic Profiling of IDH-Wild-Type Glioblastoma Reveals a Composite Surgical Sampling Signature Shaped by Clinical and Anatomical Tumor Features

    doi: 10.3390/metabo16050296

    Figure Lengend Snippet: Study flowchart. ( A ) Of 107 patients with IDH-wild-type glioblastoma and available HRMAS spectra, 8 were excluded because the analyzed specimen corresponded to a tumor recurrence rather than the initial diagnosis, yielding a de novo cohort of 99 patients (166 spectra). Patients were classified as biopsy-only (n = 35; stereotactic sampling using the ROSA robotic platform, Zimmer Biomet, Warsaw, IN, USA) or resection (n = 64; including 40 gross-total, 21 near-total, and 3 subtotal resections performed under neuronavigation guidance). For each patient, when multiple spectra were available, patient-level metabolic profiles were computed as the median concentration across spectra. ( B ) Intratumoral metabolic heterogeneity was assessed in the 44 patients with at least two HRMAS spectra from the same surgical episode, yielding 107 intra-patient pairwise comparisons.

    Article Snippet: In biopsy-only cases, stereotactic sampling was performed using the ROSA robotic platform (Zimmer Biomet, Warsaw, IN, USA), whereas in resection cases, tissue sampling was performed under neuronavigation guidance.

    Techniques: Biomarker Discovery, Sampling, Concentration Assay